Aims Sodium-glucose co-transporter-2 (SGLT-2) inhibitor-induced weight loss might play a
role in the debated elevated fracture risk with these agents. The aim of the current study was …

Aim To evaluate the association between sodium–glucose cotransporter-2 (SGLT2)
inhibitors and risk of bone fractures in patients with type 2 diabetes mellitus (T2DM) …

Background Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk. It is
debated whether sodium-glucose cotransporter 2 (SGLT2) inhibitors influence fracture risk …

Abstract Aims/Introduction This study aimed to determine whether sodium–glucose
cotransporter 2 inhibitors (SGLT2i) were related to increased fracture risk in adults with type …

Aim Some clinical trials have shown that sodium‐glucose cotransporter‐2 (SGLT2) inhibitors
are associated with fracture risk. However, this notion remains controversial. This study …

This meta-analysis aims to evaluate the impact of Sodium Glucose Transporter 2 (SGLT2)
inhibitors on fractures, bone mineral density (BMD), and bone metabolism markers in type 2 …

Background Sodium‐glucose cotransporter 2 (SGLT2) inhibitors could potentially alter
calcium and phosphate homeostasis and may increase the risk of bone fracture. Methods …

Background The aim of the study is to update and determine the effects of sodium glucose
cotransporter 2 (SGLT2) inhibitor therapy on fracture and bone mineral density (BMD) in …

Aim To perform a systematic literature review and network meta-analysis (NMA) of
randomized controlled trials (RCTs) to estimate effect of SGLT2 inhibitors on fracture risk in …

Purpose To determine the risk of fractures associated with sodium‐glucose co‐transporter 2
inhibitors (SGLT2i) compared with dipeptidyl peptidase‐4 inhibitors (DPP4i). Methods We …